Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors.
Future Oncol
; 19(26): 1801-1807, 2023 Aug.
Article
en En
| MEDLINE
| ID: mdl-37737023
ABSTRACT
Aims/purpose:
Leptomeningeal metastases (LM) are associated with substantial morbidity and mortality. Several approaches are used to treat LM, including intrathecally administered therapies. We consolidated current studies exploring intrathecal therapies for LM treatment. Patients &methods:
A review of clinical trials using intrathecal agents was conducted with outcomes tabulated and trends described. 48 trials met the inclusion criteria. Initial investigations began with cytotoxic agents; following this were formulations with longer cerebrospinal fluid half-lives, targeted antibodies and radionucleotides. Results &conclusion:
Outcomes were not reported consistently. Survival, when reported, remained poor. Intrathecal therapies for LM remain a viable option. Their use can be informed by an understanding of efficacy, safety and toxicity. They may be an important component of future LM treatments.
This paper summarizes the findings from 48 clinical trials conducted since the 1970s about the treatment of leptomeningeal metastases through an intrathecal approach (administering drugs directly into the cerebrospinal fluid a fluid that surrounds the brain and spinal cord). The results of these studies suggest that although these therapies show promise for the future, they currently do not clearly and consistently report a benefit. Further work is needed to explore the possible use of these treatments.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Líquido Cefalorraquídeo
/
Neoplasias Meníngeas
/
Neoplasias
Idioma:
En
Revista:
Future Oncol
Año:
2023
Tipo del documento:
Article